Navigation Links
SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year

NATICK, Mass. and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the results of additional data from the SPIRIT FIRST, II and III Clinical Trials, reaffirming prior safety and efficacy data for the market-leading TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System and XIENCE(TM) V (PROMUS(TM)) Everolimus Eluting Coronary Stent System. The PROMUS Stent is a private- labeled XIENCE(TM) V Stent, manufactured by Abbott and distributed by Boston Scientific. Boston Scientific is the only company to offer the choice of two distinct drug-eluting stent platforms.

The data were presented by Gregg W. Stone, M.D., Chairman and Chief Medical Officer of the Cardiovascular Research Foundation, Medical Center, New York City, at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

The SPIRIT FIRST three-year clinical follow-up results provided further support for the safety and efficacy of the XIENCE V (PROMUS) Stent, with no additional MACE since one-year follow up. In addition, no acute, sub-acute or late stent thrombosis was seen in either the XIENCE V (PROMUS) or BMS control group through three years.

Dr. Stone's presentation also included results of a pooled analysis of previously reported SPIRIT II and III data, where stent thrombosis rates were shown to be very low for both stents (0.45 percent for the XIENCE V (PROMUS) Stent and 0.25 percent for the TAXUS Stent, p=0.59).

"It is reassuring to see that both stents performed exceptionally well in the SPIRIT Clinical Trials on multiple safety measures including stent thrombosis," said Jeff Goodman, President of International for Boston Scientific. "The data for these two drug-eluting stent platforms continue to reinforce Boston Scientific's leadership position in drug-eluting stent tech nologies. We also look forward to Abbott presenting and publishing subset data from the SPIRIT Clinical Trials."

The PROMUS Stent has CE Mark approval and is distributed in most European countries and other international markets. The XIENCE V (PROMUS) Everolimus Eluting Coronary Stent System is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008.

SPIRIT is sponsored by Abbott. TAXUS, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories group of companies.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.


     CONTACT:  Paul Donovan

               508-650-8541 (office)

               508-667-5165 (mobile)

               Media Relations

               Boston Scientific Corporation


               Dan Brennan

               508-650-8538 (office)

               617-459-2703 (mobile)

               Investor Relations

               Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Paul Donova n, Media Relations, +1-508-650-8541 office,+1-508-667-5165 mobile, or Dan Brennan, Investor Relations, +1-508-650-8538office, +1-617-459-2703 mobile, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com//

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... Va. , May 24, 2017  ivWatch ... Original Equipment Manufacturer (OEM) Board to enable seamless ... with patient monitoring systems, infusion pumps and other ... OEMs will be able to help health care ... and reduced risks related to IV therapy. ...
(Date:5/22/2017)... May 22, 2017  Lilac Corp, the company ... the launch of a new website . ... of a clinical study that showed surprising clearance ... Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, precancerous, ... there are no other treatments that clear the ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 18, 2017  Two ... Healthcare Businesswomen,s Association (HBA) during its recent 28 th ... New York City.  The event showcases HBA,s longstanding mission ... the business of healthcare. Cindy Powell-Steffen ... in Bayer,s U.S. Radiology division, and Libby Howe ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider of ... with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep device ... this platform, initializing devices and importing studies are just one-click operations. This plugin ...
(Date:5/26/2017)... ... 2017 , ... On May 24, the Congressional Budget Office (CBO) projected that ... May 4, would result in 23 million Americans losing their health insurance by 2026 ... Protection and Affordable Care Act (ACA). , “It is clear from the CBO ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Rob Lowe acts ... upcoming production of the series is on hiking in American. Viewers can reconnect with ... the great benefits of hiking. , Many consumers have looked for an inventive new ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
Breaking Medicine News(10 mins):